Paronychia
- May 2022
- 15min
Therapeutic classes inducing this adverse event
EGFR inhibitor, MEK inhibitor, mTOR inhibitor, Chemotherapy
CTCAE V5.0
Nail fold edema or erythema; disruption of the cuticle
SIMPLIFIED GRADING
Painless
Isolated edema or erythema
References
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
CTCAE V5.0
Local intervention indicated; oral intervention indicated (e.g., antibiotic, antifungal, antiviral); nail fold edema or erythema with pain; associated with discharge or nail plate separation; limiting instrumental ADL
SIMPLIFIED GRADING
Moderate pain (VAS <6) or discharge or nail plate separation or asymptomatic pyogenic granuloma or limiting instrumental ADL
References
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
CTCAE V5.0
Operative intervention indicated; IV antibiotics indicated; limiting self care ADL
SIMPLIFIED GRADING
Severe pain (VAS ≥ 6) OR Symptomatic pyogenic granuloma OR Limiting self care ADL
References
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
Browse for more adverse events